Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Mendel Jansen"'
Autor:
Chris H. Takimoto, Sridhar Mani, Dale E. Shuster, Mendel Jansen, Fang Fang, Christopher Desjardins, Nancy Wong, Quincy S. Chu, Eric K. Rowinsky, Monica Mita, Alain C. Mita, Sanjay Goel
Editorial on this Article from A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a351f344895b818e22174cb35314bb7
https://doi.org/10.1158/1078-0432.22440229.v1
https://doi.org/10.1158/1078-0432.22440229.v1
Autor:
Chris H. Takimoto, Sridhar Mani, Dale E. Shuster, Mendel Jansen, Fang Fang, Christopher Desjardins, Nancy Wong, Quincy S. Chu, Eric K. Rowinsky, Monica Mita, Alain C. Mita, Sanjay Goel
Purpose: Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This phase I study deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a73b8975cba01930f10a01137a7d5fa
https://doi.org/10.1158/1078-0432.c.6517579.v1
https://doi.org/10.1158/1078-0432.c.6517579.v1
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Berzosertib (formerly M6620) is the first-in-class inhibitor of ataxia–telangiectasia and Rad3-related protein, a key component of the DNA damage response, and being developed in combination with chemotherapy for the treatment of patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::061b976ffbafd90bef8404a30d1d2cf2
https://doi.org/10.1007/s00280-020-04184-z
https://doi.org/10.1007/s00280-020-04184-z
Autor:
Jeanne Mendell, Alexander Currie, James Dow, Domenico Merante, Hamim Zahir, Hitoshi Ishizuka, Mendel Jansen, Ling He, Victor Dishy
Publikováno v:
Clinical Pharmacology in Drug Development. 7:597-612
Four randomized, double-blind, placebo-controlled, 4-period drug-drug interaction studies were conducted in healthy subjects to evaluate the pharmacokinetic and pharmacodynamic (PD) interactions between mirogabalin and commonly used central nervous s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ed9c83682030ea70bcb781f9f393ce0
https://doi.org/10.1002/cpdd.582
https://doi.org/10.1002/cpdd.582
Autor:
Victor Dishy, Hitoshi Ishizuka, Lisa Johnson, SJ Warrington, Karen Brown, Shoichi Ohwada, Mendel Jansen
Publikováno v:
Clinical Pharmacology in Drug Development. 7:661-669
Mirogabalin is a novel, preferentially selective α2 δ-1 ligand under investigation to treat neuropathic pain. The purpose of this study was to evaluate the safety, tolerability, and pharmacokinetics of various doses of mirogabalin in healthy subjec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d1f595b3c9b9bee141fa5bc89eda49a
https://doi.org/10.1002/cpdd.448
https://doi.org/10.1002/cpdd.448
Autor:
Alexander G. Vandell, Mendel Jansen, Anthony J. Olszanski, Johanna C. Bendell, Esther Zwick-Wallasch, Giorgio Senaldi, Kathleen N. Moore, Patricia LoRusso
Publikováno v:
Investigational new drugs. 37(1)
U3-1565 is a monoclonal antibody directed against heparin-binding epidermal growth factor-like growth factor (HB-EGF), which mediates angiogenesis via induction of vascular endothelial growth factor (VEGF-A). This first-in-human study characterized t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5ffc16ec683dcf6c737c5479d128d3da
https://pubmed.ncbi.nlm.nih.gov/30056611
https://pubmed.ncbi.nlm.nih.gov/30056611
Autor:
Rira Watanabe, Archie N. Tse, David C. McKee, Mendel Jansen, Sze Ting Lee, Graeme O'Keefe, Martin W. Brechbiel, Fook-Thean Lee, Niall C. Tebbutt, Geoffrey Chong, Andrew M. Scott, Marika Ciprotti, Wendie Hopkins, Manabu Matsumura, Jonathan Greenberg, Fiona Scott, Masakatsu Kotsuma, Sylvia J. Gong, Ralph Venhaus, Bridget Chappell, Robert A. Beckman, Hui K Gan
Publikováno v:
Journal of Clinical Oncology. 33:2609-2616
Purpose CS-1008 (tigatuzumab) is a humanized, monoclonal immunoglobulin G1 (IgG1) agonistic antibody to human death receptor 5. The purpose of this study was to investigate the impact of CS-1008 dose on the biodistribution, quantitative tumor uptake,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c4a460e06bb02d6fee7877c9145523b
https://doi.org/10.1200/jco.2014.60.4256
https://doi.org/10.1200/jco.2014.60.4256
Autor:
Ron J. Keizer, Jos H. Beijnen, Jan H.M. Schellens, Alwin D. R. Huitema, Jantien Wanders, Mats O. Karlsson, Mendel Jansen, Anubha Gupta, Melvin R. Mac Gillavry
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics
Hypertension and proteinuria are commonly observed side-effects for anti-angiogenic drugs targeting the VEGF pathway. In most cases, hypertension can be controlled by prescription of anti-hypertensive (AH) therapy, while proteinuria often requires do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::148e5838a6b49eb6306a6e0c8b3d3aa2
https://doi.org/10.1007/s10928-010-9164-2
https://doi.org/10.1007/s10928-010-9164-2
Autor:
Fang Fang, Dale E. Shuster, Sanjay Goel, Chris H. Takimoto, Alain C. Mita, Christopher DesJardins, Nancy Wong, Mendel Jansen, Eric K. Rowinsky, Sridhar Mani, Quincy Siu-Chung Chu, Monica M. Mita
Publikováno v:
Clinical Cancer Research. 15:4207-4212
Purpose: Eribulin mesylate (E7389), a non-taxane microtubule dynamics inhibitor, is a structurally simplified, synthetic analogue of halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This phase I study deter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::aeabe16c24f92ba9b151c525997d35b0
https://doi.org/10.1158/1078-0432.ccr-08-2429
https://doi.org/10.1158/1078-0432.ccr-08-2429
Publikováno v:
Cancer chemotherapy and pharmacology. 77(5)
The purpose of this analysis was to develop a population pharmacokinetic (PK) model for patritumab, a fully human monoclonal antibody that targets human epidermal growth factor receptor 3. A total of 833 serum concentrations were included in this ana
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d70b48f97b969a156ddd9f6081a4c841
https://pubmed.ncbi.nlm.nih.gov/27017616
https://pubmed.ncbi.nlm.nih.gov/27017616